EACH YEAR MILLIONS OF PEOPLES CROSS THE ROAD TO GET TO THEIR DESTINATION-SOME DRUNK SOME LAME SOME BLIND SOME DEAF. WE CONDUCTED A RETROSPECTIVE STUDY TO SEE IF CROSSING THE ROAD WAS ASSOCIATED WITH MORE DEATH THAN NOT CROSSING THE ROAD. WE FOUND THAT MORE PEOPLE DIES CROSSING THE ROAD THAN NOT CROSSING THE ROAD. ITS TIME TO PAUSE ON CROSSING ROADS UNTIL RANDOMIZED STUDIES CAN ASSURE US THAT CROSSING THE ROAD IS OF NET BENEFIT TO US. TRU TRUE AND NOT REALLY. WE ALL NEED TO MAKE A STUDIED DECISION ON WHERE AND WHEN TO USE DIGOXIN A RANDOMIZED STUDY CAN NEVER RANDOMIZE THE EXACT STUDY PATIENTS ANY OF US MEETS AS PHYSICIANS ACROSS THE WORLD. IF WE ARE REALLY GOING TO CAN A GOOD DRUG THAT HAS BEEN USED WELL BY EXPERIENCED CLINICIANS ACROSS THE WORLD BY SAYING THAT IT MIGHT CAUSE AN INCREASE IN MORTALITY WE NEED BETTER DATA THAN THIS "MATCHED" RESPECTIVE COHORT STUDY.....KRUMHOLZ SAYS "ANY USE OF DIGOXIN IN THIS SETTING (AFIB NEWLY DX'D) REQUIRES SPECIFIC JUSTIFICATION OF WHY THE BENEFITS OUTWEIGH THE POTENTIAL RISKS"-ALSO TRUE OF ALL DRUGS WE USE FOR AFIB INCLUDING THE ANTICOAGULANT-THE ART NOT SCIENCE OF MEDICINE IS STILL ALIVE.....
Study Offers Little Support for Digoxin in Atrial Fibrillation — Physician’s First Watch
Study Offers Little Support for Digoxin in Atrial Fibrillation
By Larry Husten
Digoxin is associated with increased mortality among patients with atrial fibrillation, according to a retrospective study in the Journal of the American College of Cardiology.
Researchers examined data on more than 122,000 patients in the Veterans Affairs system who had newly diagnosed AF. During 350,000 patient-years of follow-up, roughly one-quarter of the patients died. Nearly 29,000 patients who received digoxin were matched with an equal number of controls who did not. The risk for death was higher among digoxin recipients — a finding that remained significant after multivariable adjustment (hazard ratio, 1.21).
Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, said, "This study raises concerns about the safety of digoxin in the treatment of patients with atrial fibrillation. Given the range of medications available, any use of digoxin in this setting should require specific justification indicating why the benefits outweigh the potential risks. It's time to pause on digoxin until studies can assure that it is providing a net benefit to these patients."
Reader Comments (8)
As any drug, digoxin has side effedts, but the auther did not mention the inclusion or exclusion criteria of the study ???. Why the auther did not compare digoxin with other rate limiting drug(s) in AF?.
Excellent site. Strong information.
This is a poorly based conclusion. An more important parameter was not included: how were the digoxin treated patients matched with those also anticoagulated. Quite likely those who received dig had a higher incidents of non-anticoagulation, or poorly verified anticoagulation, which in and of itself, raises mortality.
I have now spent 15-20 minutes trying to find this article or at least the name of authors and an abstract without success. In these comments to article you normally find the name of authors, the title etc. The LINK to JACC give me 13 onlinefirst-articles, none about digoxin...
Have any randomized controlled trials looked at digoxin, A-fib and mortality?
If some one does not know how to use a camera properly then the fault is not with the camera but with the person who uses it, similarly digoxin which has a narrow therapeutic window causes side effects and toxicity if not used properly.This is the oldest cardiac drug but due to improper dose it causes toxicity.one never knows whether the disease killed or the drug killed those patients.